Amarantus Bioscience Holdings Inc (AMBS)

[guardiangel]

Zoom..The IP is important..What makes it an issue is that GW Medical Technologies a Corporation that William is still associated with is currently the owner of a Federal Trademark that AMBS is using. Apparently William is allowing AMBS to use the Trademark on some sort of condition or purpose...According to GC. It is AMBS's trademark..If that was the case then GW and William should have surrendered the Trademark to AMBS..That is not the case...This is why we think the Diagnostics division will be spun off to William and the ProvistaDX Angel investors..This is just one man's opinion..If AMBS owned the Trademark, it would appear on the GW trademark history..As of today it is a fact that AMBS is using the trademark owned by William and GW and not AMBS as GC had stated in an email last August...We are hoping that ProvistaDX/William Gartner are the companies taking over the Diagnostics division and utilizing Radient Pharma shell to take all of these concerns public...imo Wolf

http://www.amarantus.com/diagnostics/lympro-test

This is an interview with William after he sold PDX to angel investors..He remains as a VP of Development with ProvistaDX..He has started a company GCDX with the IP collaboration between Radient and PDX lung cancer test. How can he sell the same test through GCDX with the IP that ProvistaDX still owns..

http://www.bizjournals.com/phoenix/print-edition/2011/12/30/provista-to-go-public-with-breast.


The Great Recession seems to have been more of a nuisance than a hindrance to Provista Life Sciences President and CEO Will Gartner.

“The recession only affected us from the standpoint that it became more work to raise capital,” said Gartner, whose 8-year-old company brought a breast cancer blood test to market in 2009 and is working on similar diagnostics for lung cancer and Alzheimer’s disease. “In the phase we were in, it’s not like the economy reduced our revenue — we didn’t have a product to sell yet.”

Recently, Gartner sold Phoenix-based Provista Life Sciences LLC’s breast and lung cancer testing technologies to a new company called Provista Diagnostics Inc., which he intends to take public by the middle of next year.

The lung cancer blood test still is in clinical trials, but Gartner hopes the new company will help the breast cancer blood test penetrate the commercial market.

Meanwhile, Provista Life Sciences will continue developing neurological-disorder diagnostic tools, such as the blood test to help doctors detect Alzheimer’s disease, which is not yet on the market.

Gartner said he wasn’t bothered much by the lack of venture capital funding that occurred during the recession, preferring instead to work with equity capital firms, angel investors and family institutional investors.

“The money was there, but people were scared and they took longer to make a decision,” he said.

Now, he’s hoping the U.S. Food and Drug Administration’s growing interest in companion diagnostic technologies like his, which can help doctors determine if certain drug therapies are working, will bode well for future financing opportunities.

“Large institutional financing sources are recognizing that diagnostics is a good field in which to invest,” Gartner said. “It’s very different than it was five years ago.”